Metropolis Healthcare Limited — Investor Meet, 20-05-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Metropolis Healthcare has announced a board meeting to consider the financial results for the quarter and half-year.

Q4 FY25 revenue rose 10% YoY to INR 345 Cr; full-year revenue grew 12% supported by 6% patient volume growth and better pricing. Adjusted EBITDA increased 5% in Q4 to INR 84 Cr, with FY25 EBITDA up 14% at INR 325 Cr. PAT (ex-one-offs) grew 24% in Q4 to INR 45 Cr and 26% for FY25 at INR 161 Cr. Recent acquisitions in North India aim to boost regional revenue to ~14-15% in FY26. B2C segment grew 17% in FY25, now 55% of revenues, with double-digit growth in specialty areas. Focus shifts from rapid lab expansion to ramping up collection centers and operational efficiency, targeting ~100bps margin improvement organically in FY26 and 25-26% revenue growth including acquisitions. Capex trimmed to INR 50-55 Cr. Management emphasizes market share gains, advanced testing, genomics, and AI diagnostics as growth drivers.